- Home
- MOLN vs ZURA Comparison
MOLN vs ZURA Comparison
Compare MOLN & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MOLN
- ZURA
- Stock Information
- Founded
- MOLN 2004
- ZURA 2022
- Country
- MOLN Switzerland
- ZURA United States
- Employees
- MOLN N/A
- ZURA N/A
- Industry
- MOLN
- ZURA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MOLN
- ZURA Health Care
- Exchange
- MOLN Nasdaq
- ZURA Nasdaq
- Market Cap
- MOLN 142.6M
- ZURA 137.2M
- IPO Year
- MOLN 2021
- ZURA N/A
- Fundamental
- Price
- MOLN $3.71
- ZURA $4.16
- Analyst Decision
- MOLN Hold
- ZURA Buy
- Analyst Count
- MOLN 1
- ZURA 9
- Target Price
- MOLN $4.00
- ZURA $11.00
- AVG Volume (30 Days)
- MOLN 2.3K
- ZURA 3.9M
- Earning Date
- MOLN 11-05-2025
- ZURA 11-06-2025
- Dividend Yield
- MOLN N/A
- ZURA N/A
- EPS Growth
- MOLN N/A
- ZURA N/A
- EPS
- MOLN N/A
- ZURA N/A
- Revenue
- MOLN $856,302.00
- ZURA N/A
- Revenue This Year
- MOLN N/A
- ZURA N/A
- Revenue Next Year
- MOLN $1,000.00
- ZURA N/A
- P/E Ratio
- MOLN N/A
- ZURA N/A
- Revenue Growth
- MOLN N/A
- ZURA N/A
- 52 Week Low
- MOLN $3.36
- ZURA $0.97
- 52 Week High
- MOLN $7.60
- ZURA $5.07
- Technical
- Relative Strength Index (RSI)
- MOLN 50.18
- ZURA 84.19
- Support Level
- MOLN $3.68
- ZURA $2.07
- Resistance Level
- MOLN $3.85
- ZURA $2.35
- Average True Range (ATR)
- MOLN 0.09
- ZURA 0.21
- MACD
- MOLN 0.00
- ZURA 0.20
- Stochastic Oscillator
- MOLN 50.00
- ZURA 95.42
About MOLN Molecular Partners AG
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.